Abemaciclib Dose Escalation to Maintain Intensity (ADE-MI)
Status:
Recruiting
Trial end date:
2030-11-01
Target enrollment:
Participant gender:
Summary
This is a post-marketing single arm, phase IV trial in which patients with high-risk
early-stage HR+HER2- breast cancer will receive adjuvant abemaciclib in combination with
endocrine therapy (ET) After study intervention, participants will remain on combination
abemaciclib + ET at the discretion of their treating providers